DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS IN Slovakia ONLY.
Information about the NuvaxovidTM JN.1 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted)
NuvaxovidTM JN.1 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) has been granted full approval by the European Commission for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
Report an Adverse Event (AE)
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of Slovakia.
Štátny ústav pre kontrolu liečiv
Sekcia vigilancie
Kvetná 11
SK-825 08 Bratislava
Tel: + 421 2 507 01 206
e-mail: neziaduce.ucinky@sukl.sk
Tlačivo na hlásenie podozrenia na nežiaduci účinok lieku je na webovej stránke www.sukl.sk v časti Bezpečnosť liekov/Hlásenie podozrení na nežiaduce účinky liekov
Formulár na elektronické podávanie hlásení: https://portal.sukl.sk/eskadra/
Contact Us
Tel: +421 2 330 579 30
09:00 - 17:00
Monday - Friday